<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39413492</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.</ArticleTitle><Pagination><StartPage>126448</StartPage><MedlinePgn>126448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126448</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01130-7</ELocationID><Abstract><AbstractText>The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 led to the coronavirus infection diseases 2019 (COVID-19) pandemic, significantly impacting global public health and the economy. Numerous COVID-19 vaccines based on the receptor binding domain (RBD) of SARS-CoV-2 spike protein have been developed, utilizing various protein expression platforms and adjuvant systems. In a previous study, we reported using the direct fusion of the A subunit of type IIb E. coli heat-labile enterotoxin with the SARS-CoV-2 RBD protein (RBD-LTA) as an intranasal vaccine candidate (Hsieh et al., 2023). In this study, we investigated the effects of an intranasal booster of RBD-LTA/RBD mixture proteins after one or two doses of intramuscular bivalent BA.4/5 mRNA vaccination over 17 and 35 weeks. Our results indicate that the intranasal RBD-LTA/RBD mixture proteins booster maintains high levels of anti-RBD IgG and neutralizing antibodies, comparable to those elicited by a two-dose mRNA vaccination regimen. An additional RBD-LTA/RBD mixture proteins booster significantly increased antibody titers, demonstrating the potential of this approach for long-term immunity against SARS-CoV-2. Our findings suggest that combining primary mRNA vaccination with an intranasal RBD-LTA/RBD mixture proteins booster can effectively sustain antibody levels over extended periods, providing a promising strategy for long-term protection against SARS-CoV-2 and its variants.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>He-Chin</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chung-Chu</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, MacKay Memorial Hospital, Hsinchu 30071, Taiwan; Teaching Center of Natural Science, Minghsin University of Science and Technology, Hsinchu 30401, Taiwan. Electronic address: 4059@mmh.org.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen-Chun</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Biomedical Translation Research Center, Academia Sinica, Taipei 11529, Taiwan. Electronic address: wenchun0617@gate.sinica.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan; Department of Medical Science, National Tsing Hua University, Hsinchu 30013, Taiwan; Adimmune Corporation, Taichung 42723, Taiwan. Electronic address: scwu@mx.nthu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fusion protein</Keyword><Keyword MajorTopicYN="N">Heat-labile enterotoxin a</Keyword><Keyword MajorTopicYN="N">Intranasal booster</Keyword><Keyword MajorTopicYN="N">Receptor binding domain</Keyword><Keyword MajorTopicYN="N">mRNA immunization</Keyword></KeywordList><CoiStatement>Declaration of competing interest The National Tsing Hua University has filed a patent application on the RBD-based COVID-19 mucosal vaccine candidates.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39413492</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126448</ArticleId><ArticleId IdType="pii">S0264-410X(24)01130-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>